Literature DB >> 17722667

Outcomes of men who present with elevated serum PSA (>20 ng/mL) to an inner-city hospital.

Satoshi Anai1, C Shawn West, Myron Chang, Kogenta Nakamura, John Pendleton, Charles J Rosser.   

Abstract

INTRODUCTION: We report the incidence, clinicopathologic features, and outcomes of men who presented to an inner-city hospital with serum PSA >20 ng/ml.
MATERIALS AND METHODS: Five-hundred-sixty men underwent a transrectal ultrasound needle-guided biopsy of the prostate for elevated PSA >4 ng/ml with or without an abnormal digital rectal examination.
RESULTS: Of the 560 men, 65 (12%) were found to have a serum PSA >20 ng/ml, and 57 (10%) were diagnosed with prostate cancer. In the group of 57 men with cancer, the positive predictive value of PSA alone was 72% for PSA levels of 20-29.99 ng/ml and 100% for PSA >30 ng/ml. Of the 57 men, 18 underwent definitive therapy, 24 underwent androgen deprivation, 8 refused treatment or were lost to follow-up, and 7 were treated on protocol. An additional seven men with cancer refused therapy or were lost to follow-up, thus giving a total of 15 (26%) men who were noncompliant to medical advice.
CONCLUSIONS: Serum PSA >30 ng/ml is an almost certain predictor of the presence of prostate cancer. Aggressive prostate cancer education and screening programs are needed in our inner cities in order to detect prostate cancer at an earlier, treatable stage.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17722667      PMCID: PMC2574301     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  15 in total

1.  Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate.

Authors:  L A Eskew; R L Bare; D L McCullough
Journal:  J Urol       Date:  1997-01       Impact factor: 7.450

2.  The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. American Society of Therapeutic Radiology and Oncology.

Authors:  E M Horwitz; F A Vicini; E L Ziaja; C F Dmuchowski; J S Stromberg; A A Martinez
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-05-01       Impact factor: 7.038

Review 3.  Androgen deprivation therapy for prostate cancer.

Authors:  Nima Sharifi; James L Gulley; William L Dahut
Journal:  JAMA       Date:  2005-07-13       Impact factor: 56.272

4.  Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing.

Authors:  Willi Oberaigner; Wolfgang Horninger; Helmut Klocker; Dieter Schönitzer; Wolf Stühlinger; Georg Bartsch
Journal:  Am J Epidemiol       Date:  2006-07-07       Impact factor: 4.897

5.  Natural history of progression after PSA elevation following radical prostatectomy.

Authors:  C R Pound; A W Partin; M A Eisenberger; D W Chan; J D Pearson; P C Walsh
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

Review 6.  Side effects of androgen deprivation therapy: monitoring and minimizing toxicity.

Authors:  Celestia S Higano
Journal:  Urology       Date:  2003-02       Impact factor: 2.649

7.  Gender and race/ethnicity affect the cost-effectiveness of colorectal cancer screening.

Authors:  Charles P Theuer; Thomas H Taylor; Wendy R Brewster; Hoda Anton-Culver
Journal:  J Natl Med Assoc       Date:  2006-01       Impact factor: 1.798

8.  Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer.

Authors:  M C Benson; I S Whang; A Pantuck; K Ring; S A Kaplan; C A Olsson; W H Cooner
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

9.  The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?

Authors:  Thomas A Stamey; Mitchell Caldwell; John E McNeal; Rosalie Nolley; Marci Hemenez; Joshua Downs
Journal:  J Urol       Date:  2004-10       Impact factor: 7.450

10.  Cancer statistics, 2006.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Carol Smigal; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2006 Mar-Apr       Impact factor: 508.702

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.